First-in-human intracochlear application of human stromal cell-derived extracellular vesicles.
J Extracell Vesicles
; 10(8): e12094, 2021 06.
Article
en En
| MEDLINE
| ID: mdl-34136108
ABSTRACT
Extracellular vesicles (EVs) derived from the secretome of human mesenchymal stromal cells (MSC) contain numerous factors that are known to exert anti-inflammatory effects. MSC-EVs may serve as promising cell-based therapeutics for the inner ear to attenuate inflammation-based side effects from cochlear implantation which represents an unmet clinical need. In an individual treatment performed on a 'named patient basis', we intraoperatively applied allogeneic umbilical cord-derived MSC-EVs (UC-MSC-EVs) produced according to good manufacturing practice. A 55-year-old patient suffering from Menière's disease was treated with intracochlear delivery of EVs prior to the insertion of a cochlear implant. This first-in-human use of UC-MSC-EVs demonstrates the feasibility of this novel adjuvant therapeutic approach. The safety and efficacy of intracochlear EV-application to attenuate side effects of cochlea implants have to be determined in controlled clinical trials.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Implantación Coclear
/
Trasplante de Células Madre Mesenquimatosas
/
Vesículas Extracelulares
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Extracell Vesicles
Año:
2021
Tipo del documento:
Article